NCT02434523 - Trial of the Treatment of Chronic Laryngitis With Amitryptiline | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Laryngeal DiseasesChronic Laryngeal Neuropathy

Interventions

DRUG

Amitriptyline

Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks

OTHER

Placebo

Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks

Trial Locations (1)

02118

Boston Medical Center, Boston